Medical devices, healthcare technology and the business of care
PMA approval · P970003

VNS THERAPY SYSTEM

LivaNova USA, Inc. · Decision date Jul 16, 1997

FDA DECISIONP970003

What did the FDA approve?

FDA records P970003 as an original PMA application. The recorded decision is approval, dated Jul 16, 1997.

FDA approval order statement

Approval for the NeuroCybernetic Prosthesis (NCP(R)) System which includes the Model 100 NCP Generator, the Model 300 Series NCP Vagus Nerve Stimulation Lead, the Model 400 Tunneling Tool, and NCP System Accessories.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Jul 16, 1997

FDA source record

Regulatory record facts

Identifier
P970003
Regulatory pathway
Premarket approval application
Product code
LYJ
Decision code
APPR
Decision date
Jul 16, 1997
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.

Product code
LYJ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P970003 received

    Application receipt date recorded by FDA.

  2. P970003 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970003

Product / regulatory recordCompanyPathwayDecision dateSource
VNS Therapy SystemP970003/S254
LivaNova USA, Inc.PMA supplementOct 2, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LivaNova USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Cyberonics Blvd., Houston, TX, 77058

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records